UK Government Caught Lying On Baby Hep B Vax Safety

[Guest guest]

http://childhealthsafety.wordpress.com/2009/04/13/uk-government-untruthful/

 

UK Government Caught Lying On Baby Hep B Vax Safety

 

The British Government has been caught lying in a news report in The Mail on

Sunday newspaper yesterday about a proposal to give 8 week old British babies

Hepatitis B vaccinations: New vaccination fears over plan to give hepatitis jabs

at eight weeks old12th April 2009.

A Department of Health spokesman was quoted claiming:-

The safety of children is always paramount whenever decisions are taken

regarding what vaccines are included as part of the child vaccination

programme.“

But 8 week old babies are not at risk from Hepatitis B, with the potential

exception of babies born to mothers from countries with claimed-to-have high

rates of infection.  Around 2000 British born infants are already being

vaccinated annually in the UK.  At risk groups are intravenous

“recreational†drug abusers and those who practice unsafe sex - which rules

out 8 week old babies.

And Hepatitis B vaccine has been shown in many peer reviewed research papers

[including from Harvard University - detailed references at end] to be

associated with numerous infant deaths  in the USA and Europe, multiple

sclerosis and numerous chronic auto-immune disorders.  These latter include

Guillain-Barre syndrome, lupus, rheumatism, blood disorders and chronic fatigue.

There has been a criminal judicial investigation in France into the adverse

effects of this vaccine.  France was the first country to introduce universal

Hepatitis B vaccination and saw effects  which included the first ever seen and

harrowing cases of childhood multiple sclerosis in France.

Research also shows that the prevalence of Hepatitis B is low in the UK,

consistent with previous estimates and suggesting that many infections were

acquired outside the UK. This all suggests Government should concentrate its

efforts on effective treatment rather than vaccination of infants against a

disease which does not affect them. Proponents of the vaccination claim rates of

Hepatitis B infection are “spiralling†but based on “estimatesâ€.

Regrettably “estimates†can be “pulled†in one direction or another

depending on which direction those responsible for the “estimates†are more

interested in seeing them move.  And in these circumstances, they can never be

justification for vaccinating all babies to protect adult drug abusers and

practitioners of unsafe sex.

Additionally, UK and EU authorities have withdrawn marketing licences for 6

Hepatitis vaccines claiming a lack of efficacy and and denying in one case

[Hexavac] any association with 6 infant deaths in Germany. The deaths were

reported in a 2005 research paper as possibly caused by the vaccine:

“Unexplained cases of sudden infant death shortly after hexavalent

vaccination.†Zinka B, Rauch E, Buettner A, Rueff F, Penning R. - Vaccine.

2005 May 18.

The most recent vaccine to lose its authorisation was last week when the

Medicines Healthcare regulatory Agency withdrew GlaxoKline’s Hepatitis B

Energix B vaccine marketing authorisation with Professor Kent Woods, chief

executive of the MHRA stating:-

The safety of the vaccine is not in question, but it is suspected to be

ineffective.†MHRA recalls GSK’s Hepatitis B vaccine - 07 Apr 2009

- Regulatory Affairs - Hays Pharma News

The other most recent vaccine to lose its European marketing authorisation was 

Quintanrix [also from GSK] in August last year. The other vaccines are: Infanrix

[GSK], Hepacare [Celltech] and Primavax [Aventis Pasteur].

So if ‘The safety of children is always paramount’ why the British

Department of Health is even contemplating such a vaccine for 8 week old babies

is beyond comprehension.â€

But there is worse to come and it shows the UK’s New Labour Government has

been irresponsible handing recently from 1st April 2009 legal power to dictate

vaccination policy exclusively to the Joint Committee on Vaccination and

Immunisation: UK Government Hands Drug Industry Control of

Childhood Vaccination.  The JCVI regrettably has a demonstrable track-record

of recklessness on safety up to and including the present day, as shown in FOI

documents: British Government’s Reckless Disregard for Child Health Safety and

UK Government Hands Drug Industry Control of Childhood Vaccination.

The DoH statement published in The Mail on Sunday is also untrue because:-

Under the new law The Health Protection (Vaccination) Regulations 2009 which

came into effect on 1st April for England only, the Secretary of State has no

power on the grounds of safety to refuse to implement or reverse any Joint

Committe on Vaccination and Immunisation recommendation

the JCVI expressly has no remit to take safety into account in its

decision-making

[that role is supposedly the MHRA's but regrettably they seem to rubber stamp a

great deal of what the drug industry come up with - as has been shown time and

again and not just with vaccines, but drugs like Seroxat - the " anti-depressant "

shown not to work compared to placebo and which causes adolescents to be 3 times

more likely to commit suicide]

the only consideration the Secretary of State can take into account in rejecting

JCVI recommendations is cost-effectiveness - not safety

contrary to the UK Department of Health claims, no childhood vaccines used on

British children have ever been tested according to the gold standard of

evidence - randomised placebo controlled clinical trials.

health officials refuse to ensure large scale studies of total health outcomes

between vaccinated and unvaccinated individuals are carried out.  These should

show differences in overall health between these groups and some medical

professionals believe this is because the studies would reveal the unvaccinated

are healthier overall and high levels of chronic diseases in vaccinated

individuals.

there is no clinical benefit to infants from Hepatitis B vaccine but infants are

put at risk of the known and unknown adverse effects

this also means doctors and nurses are being expected to behave unethically and

possibly criminally - because no caring parent will consent to a vaccine

administered to an 8 week old baby on being told there are risks but no benefits

The main reason for the new drive to more and more vaccines - and this is well

published in the trade press - is that the drug industry has been changing its

business model.  The financial markets have known for many years the old model

would fail - that of patented “blockbuster†drugs:-

the drug industry have made vaccines the new growth area because they highly

lucrative

they are drugs everyone gets - it is the same business model of Bill Gates’

Microsoft - pretty much everyone has to have Windows software - pretty much

everyone gets vax’d

and the drug industry has been working hard behind-the-scenes to pursuade

everyone - especially legislators - that they are vital when they are not and

lobbying for changes in law just like this new law - which was introduced

without Parliamentary debate and appears to be unlawful per se: UK Government

Hands Drug Industry Control of  Childhood Vaccination

Dr Marc Girard, a specialist in the side effects of drugs and commissioned as a

medical expert by French courts in the French criminal investigation into the

introduction of universal Hepatitis B vaccination in France, suggests that even

in high-endemic countries, the risk/benefit ratio of what he describes as

“this unusually toxic vaccine†must be carefully re-assessed.

Regarding the health situation in the UK Dr Girard says the conclusion not to

vaccinate is obvious. France was the first country to implement universal

hepatitis B vaccination in 1994.

Whilst other evidence is embargoed by the French Courts, Dr. Marc Girard has

also been able to publish a scientific review of the unembargoed evidence of the

vaccine’s hazards (Autoimmun Rev 2005; 4: 96-100). Dr Girard shows that French

health authorities suppress studies demonstrating serious risks.

Dr Girard has previously said:

Whilst the risk factors for babies have changed little, there is now impressive

evidence that for a preventive measure, hepatitis B vaccine is remarkable for

the frequency, variety and severity of complications from its use. The toxicity

of this vaccine is so unusual that, even if crucial data are regrettably

concealed or covered by Court order, scientific evidence is already far higher

than normally needed to justify severe restrictive measures.“

______________________________________

REFERENCES

UK & EU MARKETING AUTHORISATION WITHDRAWALS

MHRA recalls GSK’s Hepatitis B vaccine - 07 Apr 2009 - Regulatory Affairs -

Hays Pharma News

Public Statement on Quintanrix (Common name: diphtheria, tetanus, pertussis,

hepatitis B, Haemophilus influenzae type b conjugate vaccine) Withdrawal of the

Marketing Authorisation in the European Union - 29/08/08 - EMEA/424484/08

EMEA announces recommendation for suspension of the marketing authorisation for

Hexavac - EMEA/297369/2005

EMEA Questions and Answers on the suspension of Hexavac -  EMEA/304888/2005

EMEA Withdrawal of the Marketing Authorisation for the Medicinal Product

Hepacare (Triple hepatitis B recombinant vaccine)EMEA/32933/02- 20/12/02

Public Statement on Hepacare (Triple hepatitis B recombinant vaccine)17/12/02 -

EMEA/32933/02

Withdrawal of the Marketing Authorisation for the Medicinal Product Primavax

(Diptheria, Tetanus, and Hepatitis B vaccine) - 04/12/00 - EMEA/H/2681/00

______________________________________

DEATHS, MULTIPLE SCLEROSIS AND OTHER ADVERSE EFFECTS

“Unexplained cases of sudden infant death shortly after hexavalent

vaccination.†Zinka B, Rauch E, Buettner A, Rueff F, Penning R. - Vaccine.

2005 May 18

Vaccinations are considered to be the most effective and safe method preventing

infectious diseases. Although hexavalent vaccines like Hexavac(®) and Infanrix

Hexa(®) are assumed to be well tolerated and safe regarding the rate of

immunity  [Liese JG, Stojanov S, Berut F, Minini P, Harzer E, Jow S, et al.

Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP-T-HBs)

administered at 2, 4, 6 and 12-14 months of age. Vaccine 2002;20:448-54; Mallet

E, Fabre P, Pines E, Salomon H, Staub T, Schodel F, et al. Immunogenicity and

safety of a new liquid hexavalent combines vaccine compared with separate

administration of reference licensed vaccines in infants. Pediatr Infect Dis J

2000;19:1119-27], it was noticed that several cases of death occurred shortly

after the vaccination. We report six cases of sudden infant death that occurred

within 48h after hexavalent vaccination. At post-mortal examination, those cases

showed unusual findings,

especially in the brain and in laboratory tests. Crude calculations of local

epidemiology are compatible with an association between hexavalent vaccination

and unusual cases of sudden infant death. If confirmed in systematic studies,

our findings would have potentially serious clinical implications.

Neonatal Deaths After Hepatitis B Vaccine - The Vaccine Adverse Event Reporting

System, 1991-1998 - Arch Pediatr Adolesc Med. 1999;153:1279-1282

Results: Of 1771 neonatal reports, there were 18 deaths in 8 boys and 9 girls (1

patient unclassified). The mean age at vaccination for these 18 cases was 12

days(range, 1-27 days); median time from vaccination to onset of symptoms was 2

days (range, 0-20 days); and median time from symptoms to death was 0 days

(range, 0-15 days). The mean birth weight of the neonates (n = 15) was 3034 g

(range, 1828-4678 g). The causes of death for the 17 autopsied cases were sudden

infant death syndrome for 12, infection for 3, and 1 case each of intracerebral

hemorrhage, accidental suffocation, and congenital heart disease. Conclusion:

Few neonatal deaths following HepB vaccination have been reported, despite the

use of at least 86 million doses of pediatric vaccine given in the United States

since 1991. While the limitations of passive surveillance systems do not permit

definitive inference, these data suggest that HepB immunization is not causing a

clear increase in

neonatal deaths.

Recombinant hepatitis B vaccine and the risk of multiple sclerosis

NEUROLOGY 2004;63:838-842

A prospective study

A. Hernán, MD, DrPH, S. Jick, DSc, J. Olek, DO and Hershel

Jick, MD

From the Department of Epidemiology (Dr. Hernán), Harvard School of Public

Health, Boston; Boston Collaborative Drug Surveillance Program (Drs. S.

Jick and Hershel Jick), Boston University, Lexington, MA; and Department of

Neurology (Dr. Olek), College of Medicine, University of California, Irvine.

Background: A potential link between the recombinant hepatitis B vaccine and an

increased risk of multiple sclerosis (MS) has been evaluated in several studies,

but some of them have substantial methodologic limitations.

Methods: The authors conducted a nested case-control study within the General

Practice Research Database (GPRD) in the United Kingdom. The authors identified

patients who had a first MS diagnosis recorded in the GPRD between January 1993

and December 2000. Cases were patients with a diagnosis of MS confirmed through

examination of medical records, and with at least 3 years of continuous

recording in the GPRD before their date of first symptoms (index date). Up to 10

controls per case were randomly selected, matched on age, sex, practice, and

date of joining the practice. Information on receipt of immunizations was

obtained from the computer records.

Results: The analyses include 163 cases of MS and 1,604 controls. The OR of MS

for vaccination within 3 years before the index date compared to no vaccination

was 3.1 (95% CI 1.5, 6.3). No increased risk of MS was associated with tetanus

and influenza vaccinations.

Conclusions: These findings are consistent with the hypothesis that immunization

with the recombinant hepatitis B vaccine is associated with an increased risk of

MS, and challenge the idea that the relation between hepatitis B vaccination and

risk of MS is well understood.

Received March 31, 2004. Accepted in final form May 8, 2004.

“Multiple sclerosis and hepatitis B vaccination: Adding the credibility of

molecular biology to an unusual level of clinical and epidemiological

evidence†Comenge Y; Girard M (Med Hypotheses, doi 10.1016/j.mehy.2005.08.012)

“Autoimmune hazards of hepatitis B vaccine†Girard M (Autoimmun Rev 2005;

4:96-100) (Text available in electronic form on request.)

______________________________________

Low Prevalence in The UK of Hepatitis B and Infections acquired abroad

The prevalence of hepatitis B infection in adults in England and Wales -

Epidemiology and Infection (1999), 122:133-138 Cambridge University Press

Cost effectiveness analyses of alternative hepatitis B vaccination programmes in

England and Wales require a robust estimate of the lifetime risk of carriage. To

this end, we report the prevalence of infection in 3781 anonymized individuals

aged 15–44 years whose sera were submitted in 1996 to 16 microbiology

laboratories in England and Wales. One hundred and forty-six individuals (3·9%)

were confirmed as anti HBc positive, including 14 chronic carriers (0·37%). The

prevalence of infection and carriage was higher in samples collected in London

and increased with age. No increased risk of infection was seen in sera from

genito-urinary (GUM) clinics. Only 15 sera positive for hepatitis B were also

positive for hepatitis C. Our results confirm the low prevalence of hepatitis B

in England and Wales, are consistent with previous estimates of carriage and

suggest that many infections were acquired while resident outside the UK. Future

prevalence studies

should determine the country of birth and other risk factors for each

individual in order to confirm these findings.  (Accepted September 14 1998)

Filed under: ADHD, Aspergers, Barak Obama, Child Health Safety, Disease

Statistics, Hannah Poling, Poling, MMR, Obama, Vaccine Damage, Vaccines,

autism, vaccination, vaccine, vaccine court | Tagged: Vaccines, Vaccine Damage,

Hannah Poling, Jon Poling, Kirby, autism, MMR, vaccination, vaccine, ADHD,

Aspergers, immunisation, vaccine adverse reaction, vaccine risks, Obama, Barak

Obama, Gerberding, CDC, genetic, genetics, Baron Cohen, Simon Baron Cohen,

Professor Baron Cohen, Professor Simon Baron Cohen, research fraud, fraud,

research, Wakefield, Wakefield

« Government Risks Male Sterility As Mumps Vaccine Fails

One Response to “UK Government Caught Lying On Baby Hep B Vax Safetyâ€

A Bradford, on April 13th, 2009 at 3:54 am Said:

I ask again, ‘do the proponents of these poisons have their own family members

vaccinated with the products. If so, knowing the dangers, are they not guilty of

aggravated assault and in more serious outcomes, ‘manslaughter’?

Public apathy has the population ’sleepwalking’ into oblivion. With the

autoimmune system compromised ‘big pharma’ will just keep coming up with

another fix to correct the damage that they cause thus another money making

product is born. Time for a new revolution. Everyone who reads this material

should contact their MP/MEP. There is a huge - often unpleasant - group who

protest about animal rights. Where are the protesters for the abuse of human

health rights? The MHRA and the European authorities along with the FDA are

under the financial ‘boot’ of the pharmaceutical giants. It is these same

organisations that are also trying to ban natural herbs and foods.

Love, Gabby. :0)

http://stemcellforautism.blogspot.com/

 

" I know of nobody who is purely Autistic or purely neurotypical. Even God had

some Autistic moments, which is why the planets all spin. " ~ Jerry Newport